Two Performance Studies on Idylla™ MSI Biomarkers Selected for Publication at ASCO Conference
Non-regulated information
Biocartis Abstract on Performance Idylla™ ctRAS Liquid Biopsy Tests Selected for Oral Presentation at 2018 American Association for Cancer Research Meeting
Non-regulated information
Biocartis Establishes R&D Center in the US
Non-regulated information
Biocartis & Immunexpress Sign Partnership for a Sepsis Host Immune Response Test on the Idylla™ platform
Non-regulated information
Biocartis and Amgen Sign New Companion Diagnostic Agreement for Novel Oncology Compound
Non-regulated information
Biocartis and Amgen Sign Companion Diagnostic Agreement for Idylla™ RAS Biomarker Tests
Non-regulated information
Biocartis launches CE-marked IVD RAS liquid biopsy tests developed under partnership with Merck KGaA, Darmstadt, Germany
Non-regulated information
Idylla™ Performance Data Presented by US Key Opinion Leaders at Association for Molecular Pathology 2017 Conference
Non-regulated information
Genomic Health and Biocartis Announce Agreement to Develop an Idylla™ IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access
Inside information
Regulated information
Idylla™ Respiratory (IFV-RSV) Panel receives 510(k) clearance by US FDA